TrialGene therapy2025

Safety, efficacy, and immunogenicity of a novel IgG degrading enzyme (KJ103): results from two randomised, blinded, phase 1 clinical trials.

Mengdie Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.